other countries have taken part in trials of remdesivir.m north london is more than 1000 covid—i9 more than 1000 covid—19 patients who took part in a trial of remdesivir. this is her receiving the drug in april, and she made a rapid recovery and is shocked that the drug has been bought up by the drug has been bought up by the us. i wanted to be part of something that could potentially help everyone and i feel that now, a small percentage of the world ‘s population really will receive any benefit from it in the near future. really disappointing. remdesivir takes months to manufacture so there was already a shortage. the deal means that the american pharmaceutical company gilead 01’ pharmaceutical company gilead or reserve nearly all production in the us for us patients. it is a global problem with millions of patients affected worldwide. those patients need access to prove n those patients need access to proven treatments. for one country to dominate the access to every single treatment is beyond unfortunate. there are 110w beyond unfortunat

remdesivir takes months to manufacture, so there was already a shortage.arma company gilead will reserve nearly all production in the coming three months for us patients. covid is a global problem, with millions of patients affected worldwide. those patients need access to proven treatments. for one country to dominate the access to a single treatment is beyond u nfortu nate. there are now two drugs which are proven to be effective against covid—19, remdesivir and the steroid dexamethasone. remdesivir costs £1,900 per course of treatment, whereas dexamethasone costs just £5. remdesivir cuts the duration of symptoms from 15 to 11 days, but is not proven to reduce the risk of dying, whereas dexamethasone cuts the risk of dying by a third in the most seriously ill patients. the nhs says it has enough remdesivirfor patients who currently need it, but how long that will last is unclear. but there are ample supplies of dexamethasone, which is now the standard treatment for seriously ill covid patients. fergus walsh, bbc news. lets speak now to a primary care phy

now we have hydroxychloroquine and remdesivir.e maybe hit one out of three potentially, though we don't know the whole story on remdesivir. certainly, this is a time for congress to take a look at the way the euas have been utilized and tune up the regulations on the fda to make sure it's done appropriately in the context of the speediness needed. >> so in this final minute, i guess, my question is also, there's going to be a lot of financial incentive for various firms to get their drugs through this eua process and get them approved. how does the fda eliminate conflicts of interest in the drug approval process? make sure there's no conflicts in the decision making process? >> quite frankly, the process is infected with conflict of interest, and there's not very much that can be done about it in the following sense. we accept the idea that drug trials, trials of diagnostics or vaccines, are conducted in general by the manufacturers themselves. and so it's a given that there will be that kind of conflict of interest and companies

remdesivir takes months to manufacture, so there was already a shortage.eserve nearly all production in the coming three months for us patients. covid is a global problem with millions of patients affected worldwide. those patients need access to proven treatments. for one country to dominate the access to a single treatment is beyond u nfortu nate. there are now two drugs which are proven to be effective against covid—19, remdesivir and the steroid dexamethasone. remdesivir costs £1,900 per course of treatment, whereas dexamethasone costs just £5. remdesivir cuts the duration of symptoms from 15 to 11 days, but it's not proven to reduce the risk of dying, whereas dexamethasone cuts the risk of dying by a third in the most seriously ill patients. the nhs says it has enough remdesivirfor patients who currently need it, but how long that will last is unclear. but there are ample supplies of dexamethasone, which is now the standard treatment for seriously ill covid patients. fergus walsh, bbc news. this more than 350 elephants have died in botswana, but myste

remdesivir and the steroid dexamethasone.e risk of dying. were asked dexamethasone cuts the risk of dying by a third in the most seriously ill patients. the us continues to struggle to contain its coronavirus outbreak. america's top disease researcher, dr anthony fauci, has told the us senate that he would not be surprised if new virus cases in the country reached 100,000 per day. they are currently around 40,000. meanwhile the european union will open its borders to a number of a countries outside the bloc, and the us isn't on there. both the united states and brazil are still dealing with worsening virus outbreaks and are being kept off the list. china is on the so called ‘safe list but only with a reciprocal agreement that is still pending. the uk and four other non—eu states — switzerland, iceland, liechtenstein and norway — are automatically included as "safe". stay with us — still to come: west indies cricket legend sir everton weekes has died at the age of 95. the iconic batsman played 48 tests between 1948 and 1958 an

i think the reason the changes were made was to ensure that patients could get access to remdesivir in a timely fashion. >> would you agree that we basically -- well, this is the only drug known to successfully treat the coronavirus. should a patient be denied access to a potentially life-saving drug like remdesivir because a hospital was unable to comply with the sudden change in hhs reporting requirements? >> and, again, i'm trying to say i think the intent and the consequence of what was done was to ensure that patients aren't denied access to remdesivir, to make sure we get timely distribution to the hospitals where these the patients are. >> thank you very much. i'm exhausted my time. next, we will hear from mr. foster, i believe. you are recognized for mr mr. lukamire. >> right now we're saying far greater suicides than we are deaths from covid. seeing far greater deaths from drug overdose than are above excess than we're seeing deaths from covid. since the pandemic began chal sales have increased by more than 25% and suspected drug overdoses have climbed 18%. i've said this almo

the us government has bought almost all the world's upcoming supply of the drug remdesivir.aster from covid—19. 0ur medical correspondent, fergus walsh, is here. what does this mean? it means that for the next three months virtually all stocks of remdesivir, the antiviral drug proven to cut hospital stays for 15 to 11 days, so a proven treatment, will be in the us. the nhs has said they already have enough stock of remdesivir to treat patients here but the production coming out of gilead sciences, an american company, are going to be going to the us. fortu nately going to be going to the us. fortunately there is another drug, a steroid, dexamethasone, which is more effective and very cheap and widely available. so thankfully the old steroid drug dexamethasone is available worldwide and whereas remdesivir cost £1900 per patient, dexamethasone costs £5 per patient so we are very dexamethasone costs £5 per patient so we are very lucky and fortunate that there is another drug which is actually better. fergus walsh, thank you. the us democratic presidential candidatejoe biden has

>> my understanding is we continue to do everything to make sure remdesivir gets to all patients that would potentially benefit from it. >> do you agree they may not be able to get them to patients because of the way that the information was given in the time frame that it was given in? >> congresswoman, i would disagree. i think the reason the changes were made is to assure the individuals could get access to remdesivir in a timely fashion. >> would you agree that we basically -- well, this is the only drug known to successfully treat the coronavirus. should a patient be denied access to a potentially life saving drug like remdesivir because a hospital was unable to comply with the sudden change in hhs reporting requirements? >> and, again, i'm trying to say i think the intent and the consequence of what was done was to ensure the patients aren't denied access to remdesivir, to make sure we get timely distribution to the hospitals where the patients are. >> thank you very much. i exhausted my time. next we will hear from mr. foster, i believe. mr. luetkemeyer is next. >> thank you. i

so treatments, remdesivir, steroids, and the plasma treatment. and just a pitch if you don't mind, dana, i'd love to tell the american people those who have been exposed to covid-19 and recovered could donate plasma if it is beneficial. those are the things that are different, more testing capacity, more therapeutics and those things. fundamentally different, but still a concerning trend and really we can stop this by following the guidelines. >> you mentioned remdesivir. i want to ask you about that. the government's last scheduled shipments of remdesivir went out this week. several hospitals and hot spots like mid land, texas, miami, florida, are either running lowell or could halow or completely out of the drug. it's the only drug to work against covid-19. as you mention, how is it possible the u.s. has run out and when can these hospitals expect more shipments? >> there is remdesivir available. that's being run out of health and human services. and we've been in touch with the states and the localities to surge remdesivir to the areas that mo

what do you think are the chances, and the timescale for patients outside of us to get remdesivir?e to wait after these three months, there have been factions or sections of the company in different legions that are trying to produce it in lower or middle income countries and higher income countries. we don't want to have a situation we have people creating the drug off patent and there is no quality assurance of the medication. what does it suggest you about how the us might react if there is an effective vaccine eventually? well, that is also — the world is basically speaking that this is a competitive as opposed to collaborative move. there is a lot of concern about the potential that this is going to be the same sort of situation as with remdesivir as it would be with the vaccine, in that the us might go ahead and monopolise or take all of the medication and not make it available for other countries. similarly, it unfortunately might have the effect of pitting other countries if they develop the vaccine first, because as i understand, the uk right now is one of the leaders in t

if you look at remdesivir, some of the other things. we will have some announcements over the next two weeks. it is only hope because we have gotten such incredible results scientifically. >> is it [indiscernible] you did bring up the reports of russia having bounties on our shoulders. president trump: we had plenty of discussion. i think it was very productive. -- said the v-shaped recovery is showing signs of moderating. [indiscernible] president trump: i think the recovery has been very strong. we have set record numbers. i think it is going to be really good. if therapeutically we come up with some answers very quickly, which i think we will, then you are going to have a tremendous recovery. likewise with the vaccines. that is ahead of schedule. hass ahead of anything that taken place in terms of vaccines before. if those things happen, if just one of those events happen, you will go right back into the v. i really do believe a lot of the governors should be opening up states that are not opening. we will see what happens. it has to

but what it does not do is offer bulletproof defense of remdesivir.s is not a final conclusive study. even gilead sciences, which were the ones who conducted their own study on their own drug, it bears repeating, have not said this is conclusive proof o the efficacy of this drug, even though there have been studies in the past showing this drug is effective in treating people with advanced cases, patients who are very, very sick, not patients who are asymptomatic or not severely ill. the test doesn't include a huge control group. it doesn't include a large body of patients, and some of the effectiveness touted by the company, it says it's something like 62% more effective and decreases the fatality rate from this disease, that's a bit shaky because it's still on both sides of the trial. those given remdesivir and those who weren't. there were still sky high cases of mortality. in many ways, this isn't much to boast about. it does show once again that this drug, which has already been shown to be promising in the past, is effective. what it doesn't sho

we have the experimental drug remdesivir and decades old steroids.drugs have shown life-saving benefits for covid patients. the problem now is potential cost issues could put it out of reach of patients that need it the most. >>> an emotional welcome home for michael jansen. >> i should have been dead. >> the new york dad was one of the pandemic's early covid patients, in a coma and on a ventilator for 42 days. >> i was telling him we want you to fight. keep fighting. >> out of options michael's doctors tried remdesivir topped with a cheap steroid for inflammation. >> you have a patient dying not just from the infection, but their body's response. >> i know they saved my life. within 24 hours of getting the steroids after the other drug i showed improvement. i stabilized. >> recent clinical trials showed remdesivir can shorten the length of the disease and might save lives. hhs was sending free remdesivir directly to hospitals, but critics say hhs data isn't keeping pace with surging cases. >> the federal government should be making sure we're moving

months,the next three only remdesivir for the united states?i believe what is happening is they are creating more production right now, so there will be supplies for europe as well. >> there is s still something ununclear from eararlier this yr regarding vavaccines. was talk k the u.s. admiministrationon tried to take over a german company that produces vaccinenes. did that happen? >> my understanding is that they are -- that is fakeke news. the company r repeated that news whereverer it came from. some of our mutual enemies have not been kind us during this infection. >> meaning? >> russia, disininformation frfm rurussia, this information from china in particular has been lant vera lind than -- viri more than the virus itself. many cases since the beginning have been wrong, and they havave been t c creatn of both russia and china. >> and you believe the story about karabakh -- >> i i don't know where it as ce from. the company has repudiated it. whether it was a misunderstanding or fake news, the reality is that it is not true. >> it comes at

at remdesivir, and you look at some of the other things, but we'll have some on that over the next few weeks. yes, it's hope and it's only gotten such we've ncredible results scientifically. >> did you talk to russian resident vladimir putin, and i wanted to ask if did you bring russia having of -- [inaudible] president trump: i won't tell you what we discussed but we had plenty of discussion and i think very productive. please? today the earlier recovery is showing signs of moderating. given what we're seeing with an that the n cases recovery could be in jeopardy at all? president trump: i think the has been very strong. we've set record job numbers. it's a umbers, whether pure v or less than that i think it will be very good. we come up ically with some answers very quickly, which i think we will then ou'll have a tremendous recovery. likewise with the vaccines, do you that by the end of the year schedule, ad of ahead of schedule. if those things happen, if just one of those events happen, right back into that v and i think you'll probably in anyway. i really do believe a lot of the

department of health and human services, hhs, was sending free remdesivir directly to hospitals.ut critics say hhs data isn't keeping pace with surging cases. >> the federal government should be making sure we're moving the supplies necessary to treat those patients in the hospitals in those states. but it's not clear that those distribution mechanisms are in place. >> reporter: hospitals in these hotspot states tell nbc news they're low on this life saving drug. >> by friday we may not have any more. >> reporter: the government's supply of remdesivir will run out by september if not sooner. and the price tag is about to go up. >> we just can't trust drug companies not to try and profiteer on this pandemic. >> reporter: and doctors fear patients today won't be able to access or afford one of the only drugs with evidence behind it. >> it's not fair to a patient or a patient's family to have to think about those things when they're loved one's life is on the line. >> reporter: and craig, what we're hearing now, again, it's not just a supply issue, it's also a redistribution issue.

buying local supplies of remdesivir for the next three months. it is a drug shown to work against covid-19.he is a doctor from the who. >> there are many people aroundr the world whvery sick with this wisease, soe want to ensure that everybody has access to the necessary intventions. our said, we will reserve commentary until we have verified the nature of the contracts, but also we are aware of other agencies put in place for manufacturing in other countrs. let us look at the issues, at the implications of this. certainly, we are fully committed as an orgaon with our partners t equitable cess to life-saving interventions. anchor: more than 500 tousand treatm causes for american hospitals had been secured. the vice president explained the steps the u.s. is taking to treat those with the illness. >> we are in a better place because of the availability of therapeutics or medicines to treat peopl that have contracted the virus and are experiencing seve symptoms. dr. stephen hahn is here and he will speak about the progress that we are making, whethe

buying up stocks of gilead's remdesivir drug, some countries are seeking to reassure residents. the u.k. says it has enough resident for every nhs payment -- patient who needs it. reportinggermany is

it's saying let's look at remdesivir, hydroxychloroquine, whatever it may be, and figure out what the numbers are. let's gather the data of people who have gotten covid and figure out, where did they get it? how many people were in bars right before then? how many people were at family events? we're not being data driven and we're not being science driven, and that goes back to the incoherent way the mind of the president of the united states works. >> jake sherman, jump in. >> yeah, i just got a text message from a senior white house aide who notes that peter navarro went rogue and he bypassed the op ed approval process in writing in the nation's largest paper, "usa

remdesivir, plasma, dexamethasone, plasma, and for those patients who require oxygen, we have been able to provide for those patients. so we have felt the support from the administration that nothing has been denied to us to take care of the patients. the result is that our mortality is way below the mortality in everywhere else. gov. desantis: thank you. i think it should be said, i fatality said the case rate is, what, .66? but when you calculate that, we only capture a certain number of infections. there are obviously way more people that have an infection. so an infection fatality rate would be the fatalities divided by the estimated infections, which may mean that that is even lower, and i think that is a testament to, get up, the great work that you guys have been doing. can you talk about the evolution of how these patients have been handled? i know you did not have as many in march and april as you have seen recently, but before people were doing plasma, before people were doing the remdesivir, if someone came in in late march, what was the protocol, and how has that involved? d

one of these is remdesivir, a trial run by the nih which showed improvement in the time to survival in individuals who are hospitalized pulmonary disease. that has now been part of the standard of care in individuals with moderate to advanced disease. in addition a placebo-controlled randomized trial of dexamethizone showed improvement on individuals with respirators as well as those requiring oxygen and finally the development and testing of effective vaccines . several months ago we put together what we call a strategic approach to covid-19 vaccine research and development area and the reason we did this is because there were multiple candidate vaccines that are moving along at a very rapid pace and we wanted to make sure that they learned from each other so we made standardized protocols, common data and safety monitoring boards, common in their endpoint and the common individual efforts . there are three separate forms being pursued with government health, nucleic acid including the mrna of morgana, viral vectors such as emerald vectors andvsp and protein subunits . one of these is

remdesivir, the president loves to talk about remdesivir, icu beds. both of those are in short supply. it's not like you can will icu beds and respiratory therapists and icu nurses at the flip of a switch. that's why you need this stuff ready. you need states to remove license restrictors so people can descend on florida to help that are accurately trained. if we get lulled into a sense of complacency, what i'm worried about here is that death rate climbing because we don't have governors like governor desantis, governor ducey saying, how can i make sure my hospitals are adequately staffed? that number has been climbing and peaking in places like florida and texas, so if you have hospitalizations climbing, their likely to keep climbing unless you get policies in place now. >> that's the reason i'm asking. if you have spreads at the level of these case counts we currently do right now, the possibility is does that go even higher. i guess what i'm asking is, given what you learned the last few months, given what's learned about remdesivir, and i underst

you mentioned remdesivir before. we were a part of the original trials, the nih-supported trial, the industry-supported trial, showed remdesivir shortened time for recovery for people hospitalized with covid-19. also showed in most patients a five-day course of remdesivir is as effective as 10-day course. that of course is important because we want to protect those supplies of remdesivir as production scales up. vaccine development is proceeding as you said at a very fast pace as well. connell: right. it looks like maybe early next year we'll have something to go with but on the therapeutic side, the treatment side, that is one thing people get more excited about because time fray framewise that helps us get through the fall. this is big point of contention politically and otherwise opening up schools. in new york governor andrew cuomo came out and gave numbers. says if we're below 5% on infection rate we can open up the schools. then we heard from two districts where you are, south of where you are, same state, l.a.

we have therapeutics like remdesivir and others that are shortening the stay of those patients. we are putting fewer of those patients on ventilators. our doctors and nurses have learned quite a bit in the last four months about how to care for covid positive patients. all of that working as a team and going in the same direction means we can do that even more efficiently and create even more capacity in the system to care for more covid positive patients. so the surge is about finding a balance between caring for covid positive patients and continuing to care for everyone in the state of california. and so the last point and it's the point you have been hearing but i want to thank each and everyone of you. the best way that we can expand and have as much capacity as we need to treat covid positive and patients with covid-19 disease is to make certain we are stopping the spread of the infection in the first place. and that is all about masks and social distancing and hand hygiene. every time you do that in your home, in your neighborhood, and in your community, you are helping a

and things are happening too like the remdesivir and other elements, steroids, etc. these trends could change without our continued and relentless focus. and that's what we have, we have a relentless focus, and it's been that way from the beginning. but we've learned so much. as you know in recent weeks, we've seen a concerning rise in the cases in many parts of our south. you look at south, southwest and west, this growth in cases first began to appear in mid june primarily among 18 to 35-year-old withs, many of whom were asymptomatic. we're also facing the challenge of a significant spike in virus cases across the rest of the western hemisphere including mexico. mexico has been hit very, very, very hard. as you know, the president, a great gentleman, was here two weeks ago, and they have really been hit hard. because we've achieved a nearly fourfold increase in testing capacity in two months, we're successfully identifying more asymptomatic and mild cases. some cases so muled that you really -- so mild that you really don't even treat them. some cases with children

remdesivir, he says now we're getting more shipments of remdesivir. is he putting too much, not enough -- what do you think the emphasis is on remdesivir, is it a miracle drug? >> i wouldn't say that. when i looked at the science behind it, the paper behind it, it reduced the amount of time people were in the hospital. it didn't do anything about their mortality rate. the thing that bothers me most about this december as an emergency care doctor is whether people live or die. that's the biggest outcome to me. reducing the time people are in the hospital is a great thing. my cousin was actually just in the hospital himself and received remdesivir. hopefully it had something to do with getting him home earlier, and he's doing better now. there are other drugs. >> the steroid. >> yeah and really just oxygen, basic oxygen is one of those things that's really, really important for patient. >> what about, doctor, the fact that he noted the majority of cases, the majority of deaths as well in florida are those who are elderly, ages 65, then he technically bu

specifically on remdesivir, that drug that's made by gilead. before. it shortens recovery time. tooves a sign of hope. but now we are hearing that there hey not be may not be unfortunate in of it. does the administration need to be doing more? i know hhs said that they're purchasing 500,000 doses of it. but is that going to meet the need? >> well, look, we need to accept the fact that we're in the second wave right now. two months ago, there were about 10 states that -- where the reproduction number was above 10, meaning they had expanding epidemics. now there's 40. so we're in that second wave. there's not a clear line on how we're going to get this under control, so it makes us more dependent on technology. there's only a handful of technologies, remdesivir is one of them. we have enough of the drug if the epidemic stays at its current level and we continue to use remdesivir as it's approved for patients who are more sick and hospitalized. but if the epidemic worsens and we want to extend use of the drug to patients who aren't as ill but have

and allocating remdesivir to hospitals, based on new admissions in hospitalization. that's something they've started. they're using it much earlier. fatalities nationwide have fallen, 75% since april. that's a great number. as cases and fatalities rise in certain hard hit states, we're surging personnel, supplies, and therapeutics. we again have tremendous amount of supply. we are in very good shape and we can move them quickly. our case fatality rate has continued to decline and is lower than the european union and almost anywhere else in the world. if you watch american television, you would think that the united states was the only country involved with and suffering from the china virus. well, the world is suffering very badly, but the fact is that many countries are suffering very, very, very badly. and they've been suffering from this virus for a long time. we've done much better than most. and with the fatality rate at a lower rate than most, it's something that we can talk about, but we're working, again, with them because we're helping a lot of countries tha

remdesivir is similar -- they use it in conjunction -- they use it with convalescent plasma. it is a regimen. if you do it early, physicians believe there has been a really good sense of support, so it is important to understand that we have really moved the ball on getting remdesivir into the hospital. folks can get convalescent plasma and also have the opportunity to do that as wolpe. also important to note that, you know, covid-19, while it is obviously an important issue, there's a lot of other health issues out there. if you need health care, particularly for things like heart and stroke, what we don't want to see is people deferring that, going to hospitals where there is capacity. those people in intensive care for things other than covid who did not seek attention when they needed to and their condition worsened, and now, it is a tougher fight, so if you are somebody out there who is experiencing those symptoms, do not shirk from going in to get the medical attention that you need, and statewide, you know, we have 25% of the hospital beds available statewide, and almo

remdesivir has been proven to treat patients with covid. is there a shortage right now, and is that a concern for you? >> yeah, we're living in a really hand to mouth existence with remdesivir. we're to the point of where every day we talk about, you know, what if ten patients come in and we only have two courses, what do we do, how do we make this decision? do we do first come, first served, do we draw the names out of a hat? these are the kind of discussions we're having right now. >> oh, that's a difficult choice. have you gotten any word if you're going to get more doses of remdesivir? >> yes, we get them every week. we're just not sure when they come. it's almost like a stork dropping remdesivir on the hospital. there is no -- you know, we're not really sure what day we're getting it. we put the data in every week, every day, actually, and the central administration or federal administration determines how much each state gets. >> okay, dr. peter chin-hong with ucsf, infectious disease specialist, thanks for painting a clearer picture

. -- the convalescent plasma and remdesivir are working. what specifically are you doing to stop the spread? >> there's a lot. i'm glad you asked that. it is worth highlighting, the work we are doing each and every day. we are searching personnel to arizona and texas, california, sending remdesivir the states seeing rising case numbers. there also sending testing supplies to decrease turnaround time. going to house will be several states this week. sent 19 hhs teams to metroplex is. we are aggressively on the ground. -- to metroplexes. we are aggressively on the ground. to just a few months ago. >> why is the white house trashing dr. fauci and sending memos to reporters? withresident has gone on anonymous sources in the past. why not have the guts to trash dr. fauci with your own aims? >> i will refer you back there, tore is no [indiscernible] reporters. that question to the washington post was, president trump noted dr. fauci had made some mistakes, and we provided a direct answer to a direct question. suggested atent one point americans i

the remdesivir has proven to be terrific.s to decline and we want to push this rate even lower. the therapeutic research continues daily and new and very promising treatments including antibody treatments including antibody treatments and the use of blood thinners and steroids, loss of different things are happening and a loss of things are coming out that we wouldn't have known a number of months ago. —— a lot of things. we are doing tremendously well on therapeutic research and tremendously well on the vaccines and frankly, therapeutically or may bea and frankly, therapeutically or may be a word even beyond that word is clear, would be the best of all and we will see what happens but that would be great if we could go into the hospital and just cheer people and we are at a position where we are actually able to a certain extent with what we have right now i'm living in a very short period of time we will be able to do that. —— a word beyond that word is cure, going to the hospital are just cure people. very vigilant, where

the remdesivir has proven to be terrific. our case fatality rate continues to decline. the therapeutic research continues daily on new and promising treatments, including antibody treatments and the use of blood thinners and steroids. a lot of things are coming out that we wouldn't have known a number of months ago. we are doing tremendously well on therapeutic research and on the vaccines. frankly, therapeutic, or a word beyond that is cure would be best of all. that would be great if we could just go into the hospital and cure people. we are at a position where we are able to, with a certain extent, and we think in a short time we will be able to do that. our strategy is to shelter the highest risk americans while allowing healthier, younger citizens to return to school or work. wear our mask, socially distance and repeatedly wash your hands. practice very good sanitary means. you have to do this. you have to look at it differently. wash your hands often. i am finding more people are saying wash your hands often. we want americans to avoid packed bars and crowded indo

how is this new study different than what we've heard several weeks ago about remdesivir contributing to recovery? >> i think the main difference here is the trial design, or the study design. it's not really a trial like the mih study that was released earlier, which was not statistically different, meaning it could have been there by chance, that difference, and between the people who got the drug and the people who got placebo, no drug. what the current study is showing is a different kind of study design, which is not randomized control, which is like you don't know who is getting the drug or not. these folks knew who was getting the drug, and they compared it to another group of patients, which are large all around the world with covid. so if people are sort of uncomfortable with that study design, but nevertheless the numbers are in the right direction, and are consistent with an nih study which a more requiring russ study design showed. >> so you said there the study did show a trend toward better survival, but was the difference statistically significant here based on what the

>> it has been removed from the front lines and in focus remdesivir was priced for $2,340 per course,es change the way we see the pricing allowing access at an affordable price. the u.s. has to grapple with the fact that economically it is not viable to continue with drugs prices the way they are. >> we've seen so many deals in recent years what has jumped out is collaboration. oxford has been one of the key ones involved. do you think we'll see further collaboration? >> i'm hopeful that one of the enduring consequences is the effect of seeing the collaboration when you think about that this is a virus we knew nothing about nine months ago and now we are looking at having a vaccine in the not too distance future. in terms of m&a, i think the megamergers have not proven to do well. innovation still comes from smaller companies. when you look at gilead and what they are doing behind covid-19 and cancer and other deals happening and against this back drop it doesn't go away it's a secular theme in health care >> fascinating conversation. i appreciate your in sight thank you for joining u

doctor marc siegel, we've heard remdesivir a lot, doesn't show a lot of promise?> this is even better than the remdesivir that we saw earlier the earlier data showed decreases by four days. this decreases the death rate and decreases the amount of people that can't get on ventilators by enormous amounts. that is a sign that this is a drug and it makes health and human services look very good for getting 500,000 courses into the united states for use in every hospital in the country, it is something that i believe every hospitalized patient will be considered for now. in the other points you made about the inhaled version, i want to point out additional things, at that ends up working that will be something you could get before your hospitalized. this is an antiviral drug and before the virus starts to take off in the body, if we can block it with remdesivir, the current version is intervening. it's always a harder to give up before your hospitalized but if we can given inhalant before your hospitalized, we made prevent and need for hospitalization because it's got

remdesivir. we're putting fewer patients on ventilators. our doctors and nurses have learned quite a bit about how to care for covid positive patients. it means we can do that more efficiently. so the surge is about finding a balance between caring for covid positive patients and continuing to care for everyone in the state of california. so the last point and the point you've been hearing, and i want to thank each and every one of you, the best way to expand to treat covid positive patients and those with covid-19 disease is to stop the spread of the text in the first place and that is all about masks, social distancing and hand hygiene. every time you do that you're helping a nurse, a doctor and the community. help us to care for those in need. thank you. >> thank you. as you can see, we have an outstanding partner at a regional level, local level but statewide. the partnership is dynamic and demonstrable, not hodge in terms of the planning document but the efforts that have been tested in cert

what that speaks to is the great work of this administration with therapeutics and remdesivir, and that is what the president was pointing out. >> just a follow-up quickly. so if you don't die, is it not harmless? ms. mcenany: the president was noting the fact that the vast majority of americans who contract coronavirus will come out on the other site of this. of course he takes this very seriously. of course no one wants to see anybody in the country contract covid, which is why the administration has fought hard to make sure that is not the case with a historic response effort. >> a follow-up on his question. what is the president's position? does he think nascar made a mistake by banning the confederate flag? ms. mcenany: he said he was not making a judgment one way or the other. the intent of the tweet was to stand up for the men and women of nascar and the fans and those who have gone and the rush to judgment of the media to call some thing a hate crime when the fbi report concluded this was not an intentional racist act. it very much mirrors other times when there has been a rush

. >> analysis shows the drug remdesivir increases the chance of survival by 62%. the doctors have a limited supply. >> even though the supply of remdesivir is ramping up, we need to keep a lid with the number of new infections. >> he says we can expect the number of deaths to rise and that the country is in a much better place with tests, ppe, and treatments. >> this is not out of control, but it requires a lot of effort. you really got to stop the bars. you got to decrease restaurant capacity and physically distance. we have to have people wearing a mask in public. >> president trump wearing a mask in public for the first time saturday evening as he met with wounded service members and health care workers at walter reed military medical center. the president has been urged to set an example by wearing a mask from some in his own party and came under criticism from democrats. the biden campaign saying he was ignoring the advice of medical experts. zohreen sha, abc news, los angeles. >>> coming up on abc7 news at 5:00 a naval ship docked off san diego is continuing

those were on ventilators require oxygen, what the drug remdesivir does, used to help stop and blockirus from locating, stopping them from invading our bodies so we don't become ill and hospitalized in the latest data suggest that 74% of patients who received the medication and iv form had recovery by day 14 versus 59% who did not receive the drug, they did not recover by day 14, they just received the standard of care, it was shown to have a reduction in mortality but further studies are required, we need more test to determine is this truly beneficial versus what we call placebo effect, it is also being used with other drugs, decadron which is an anti-inflammatory and rheumatoid arthritis information as well. there is good outcome so far from the limited data that we have and also it is not the only drug that is being tested and investigated pre-we have the steroid, we also have the convalescent plasma and also antibodies which are being investigated. ultimo drugs being tested instantly encouraging news moving into the weekend. >> i went and brought another conversation a little bi

that remdesivir and other medications are working. >> two to four weeks is such a short time period. what specifically are you doing to stop the spread? >> there's a lot. and i'm very glad that you asked that, because it is worth highlighting the work we're doing each day. for one, we're surging personnel to arizona, texas, california. we already have people working in florida. surging remdesivir to states that are seeing rising case numbers and surging testing supplies to decrease ton around time. these are several items that dr. birx briefed me on. the white house will be going to several states this week. dr. birx in particular to louisiana, mississippi, alabama, georgia, south carolina. we've sent 19 hhs teams to metroplexes. eight more coming this week. so we are aggressively on the ground reacting to this virus and encouraged to see the declining mortality compared to a few months ago. jim, glad you're back. >> why is the white house trashing dr. fauci and sending out opposition research like memos to reporters? the president has gone off in the past. why not have the guts to t

what's going on with remdesivir which the federal government was supposed to be in charge of saying we're going to make sure we stock pile this so when there's a surge it gets to where it needs to go. how come that hasn't been happening and at what cost? >> it's hard to point to the logistics that has worked well here. we heard a lot about the problems with personal protective equipment initially, ventilators, and now this one medication which could potentially have some impact. so, it's really unclear. i think i did speak on background today to folks who are helping coordinate things at the level of hhs. they did say that basically bringing in more hospital information through hhs could possibly help address these sorts of problems because they would know ahead of time which hospitals are likely to need things like remdesivir or personal protective equipment. but look, it's very hard for me to be convinced. i mean, i'm a generally pretty optimistic person but nothing has worked well which is why i keep saying jonathan reiner, who is so smart and so eloquent on this, smohould be doing thi

the eu is trying to hammer out a deal with iliad for its drug remdesivir.ng us from brussels is eulla kyriakides, the commissioner for health and food safety. the trump administration has made great efforts to ensure the united states has first access to things like remdesivir and all the vaccines it has been investing in with its operation warp speed. if the u.s. is going to be first, does that mean europe will be second? stella: let me just start by saying that, in the last few months we have seen that the eu is no longer the epicenter of the covid-19 pandemic. we are seeing numbers globally lifting and since the of containment measures we are seeing similar local increases in some member states. it's very important for us to be aware that none of us are safe until all of us are safe. we need to have a global approach in handling and fighting covid-19, a global pandemic. part of this is finding an in ative and safe vaccine timely time and also looking for effective therapeutics. the eu commission is leaving no stone unturned in terms of both addressing th